Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration.

[1]  R. Gibbs,et al.  The gut mycobiome of the Human Microbiome Project healthy cohort , 2017, Microbiome.

[2]  N. Dauby.  Risks of Saccharomyces boulardii-Containing Probiotics for the Prevention of Clostridium difficile Infection in the Elderly. , 2017, Gastroenterology.

[3]  A. Evans,et al.  Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. , 2017, Gastroenterology.

[4]  J. Meis,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  L. Mcfarland.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. , 2010, World journal of gastroenterology.

[6]  Christophe Hennequin,et al.  Invasive Saccharomyces infection: a comprehensive review. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Patricia Muñoz,et al.  Saccharomyces cerevisiae fungemia: an emerging infectious disease. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Cherifi,et al.  SACCHAROMYCES CEREVISIAE FUNGEMIA IN AN ELDERLY PATIENT WITH CLOSTRIDIUM DIFFICILE COLITIS , 2004, Acta clinica Belgica.

[9]  M. Mujica,et al.  Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. , 2019, Revista Argentina de microbiologia.